导电系统节奏在患有右捆分支阻塞和心力衰竭的患者中改善心脏表现吗?
Jia Jing-Jing1, Sun Xi-Xia1, Li Tian-Zhu1
1Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Frontiers in physiology
|December 11, 2025
概括
导电系统节奏 (CSP) 是一种安全有效的治疗方法,适用于右捆支部阻塞和心力衰竭的患者. 这项研究显示,心脏功能和症状显著改善,特别是在严重减少左心室喷射率的患者中.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 右捆支部阻塞 (RBBB) 和心力衰竭 (HF) 经常并存,导致复杂的管理挑战.
- 在RBBB患者中,心室节奏可以加剧或诱导左心室功能障碍.
- 导电系统节奏 (CSP) 通过直接准心脏的自然导电系统,为传统节奏提供了一个潜在的替代方案.
研究的目的:
- 评估CSP在被诊断为RBBB和HF的患者中的可行性和安全性.
- 为了评估CSP对心脏功能和临床结果的影响,在这个患者群体.
主要方法:
- 在2018年至2023年期间,对接受CSP的HF和RBBB患者进行了回顾性研究.
- 纳入标准:心室节奏>40%和先前存在的RBBB.
- 数据收集包括心声学和心电学参数,随访至少2年.
主要成果:
- 在88.63%的患者 (n=78) 中,CSP成功进行.
- 观察到QRS持续时间,左心室喷射率 (LVEF),左心室末端透气直径和NYHA功能类 (p<0.05) 的显著改善.
- 基线LVEF≤35%的患者表现出明显的LVEF改善 (p=0.001);LVEF和ΔQRS是响应的独立预测指标.
结论:
- CSP是RBBB和HF患者的安全有效的节奏策略.
- CSP导致心脏表现和功能状态的显著改善.
- 在基线LVEF严重降低的患者中观察到特别的益处,突出显示CSP是有前途的治疗选择.
相关概念视频
Conduction System of the Heart
3.3K
The cardiac conduction system produces and transmits electrical impulses that prompt myocardial contraction, ensuring efficient heart function. This intricate system ensures that the heart beats in a coordinated and efficient manner, beginning with the atria and then the ventricles. The conduction system optimizes cardiac output by maintaining this precise sequence, which is crucial for adequate blood circulation.
This system relies on the unique properties of nodal and Purkinje cells:...
This system relies on the unique properties of nodal and Purkinje cells:...
3.3K
Conduction System of the Heart
12.4K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
12.4K
Heart Failure Drugs: β-Blockers
729
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
729
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
Pathophysiology of Cardiac Performance
1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362


